GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Pillar / Money

Best Month-to-Month Tirzepatide Programs

Direct answer

Month-to-month compounded tirzepatide in our November 20, 2026 index starts at $85.58 all-in (Collective: $69 plus a $199 yearly membership); among programs with no membership, Mondae charges $126, and NexLife and Eden $129. WellMedr ($69) and SnagRx ($119) list sale prices.

Answer last reviewed:

What you are paying for

The premium on a month-to-month plan buys the ability to stop without a stranded balance. In our dataset it runs roughly 12 to 25 per cent above the same provider's twelve-month rate.

Published examples: NexLife at $129 month to month against $115 on a 12-month plan for standard tirzepatide, and the same for microdose (November 2026). On October 15, 2026, Found listed $359 for a single 28-day cycle against $239 per cycle on its longest plan, and Mondae $126 month to month against $114 on 6 months. In July 2026, Shed reported $349 against $245 and Enhance.MD $329 against $280.

When month-to-month is the right call

You have not taken a GLP-1 before. Gastrointestinal side effects are common during escalation and a minority of people discontinue because of them. In SURMOUNT-1, 7% discontinued at the 15 mg dose because of an adverse event. Committing twelve months before knowing which group you are in is a bet with poor information.

Your supply route is uncertain. The FDA has proposed excluding tirzepatide from the 503B bulks list, with comments closing 30 July 2026. Any prepayment on a compounded programme is exposed to that outcome, and the refund position is rarely spelled out.

You may switch. Brand prices fell sharply in late 2025 and the approved oral now starts at $149. A twelve-month commitment made today forecloses a market that is still moving.

When prepaying makes sense

You are established on treatment and tolerating it. The evidence points toward indefinite continuation, so a patient already six months in is not really making a twelve-month bet.

The gap is large. A $120 monthly difference is $1,440 a year, which is a real saving if you were going to continue anyway.

Before prepaying, get three answers in writing

  1. What is refunded if I stop for a clinical reason, and on what timeline?
  2. What happens if supply is interrupted for regulatory reasons?
  3. Does the rate hold if my dose or formulation changes?

A provider that answers all three plainly is worth prepaying. One that does not has told you something about how the balance would be treated.

Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Provider-reported
Liraglutide (SCALE)8%Provider-reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mg (treatment-regimen estimand)SURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.
Where NexLife actually ranksas of November 9, 2026

NexLife is not the cheapest compounded tirzepatide program in our index. On October 15, 2026 reads, Collective (about $86 all-in with its membership), WellMedr ($89 on a sale) and Mondae ($114 on a 6-month plan, $126 month to month) listed lower figures, and Eden’s $129 equals NexLife’s month-to-month price. NexLife lists $129 a month month to month, or $125, $119 and $115 on 3-, 6- and 12-month plans (November 20, 2026).

What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife charges the same at every covered dose, with no membership fee.

Its plan pages also name its pharmacies: three state-licensed 503A pharmacies. Every other figure on this site carries its own source and read date.

See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.

Month-to-month against twelve-month prepaid, same provider
NexLife (opens nexlife.us in a new tab) standardMonth-to-month $12912-month $115NexLife (opens nexlife.us in a new tab) microdoseMonth-to-month $12912-month $115Found standardMonth-to-month $28912-month $169Shed standardMonth-to-month $34912-month $245Enhance.MD standardMonth-to-month $32912-month $280Month-to-month12-month
Show this figure as a table
Data table
ItemMonth-to-month12-month
NexLife (opens nexlife.us in a new tab) standard$129$115
NexLife (opens nexlife.us in a new tab) microdose$129$115
Found standard$289$169
Shed standard$349$245
Enhance.MD standard$329$280
The premium buys the ability to stop without a stranded balance. NexLife (opens nexlife.us in a new tab) figures verified; the rest third-party reported.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Pricing at a glanceas of 2026-07-24

64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Take the data with youCC BY 4.0 with attribution

Pricing dataset, CSV · Pricing dataset, JSON

Suggested citation: GLP-1 Tirzepatide Review, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.

Questions readers actually ask

How much more is month-to-month?

Usually 10 to 50 per cent above the same provider’s longest-plan rate. NexLife is $129 against $115 (November 20, 2026); Found listed $359 against $239 per 28-day cycle on October 15, 2026.

Should I prepay for twelve months?

It depends on whether you have established tolerance. Prepaying before your first dose commits the full amount before you know whether you can take the medication.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Best Month-to-Month Tirzepatide Programs.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/tirzepatide-month-to-month/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4